Regel Therapeutics Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Regel Therapeutics is a Cambridge, Massachusetts-based biotechnology company focused on developing therapies for severe genetic diseases. It pursues an approach to targeted epigenetic editing intended to modulate gene regulation in disease pathways. By applying precise regulatory modifications, the company seeks to broaden therapeutic options for patients affected by genetic conditions. The company serves researchers and developers in biotech and pharmaceutical fields seeking new treatment modalities, situating itself within the biotechnology research sector. In June 2024, Regel Therapeutics announced the appointment of Stephen J. Farr as Chief Executive Officer.